Organovo

Company

Last mentioned: Mar 7, 2026

Timeline

  1. Pipeline Potential Report

    Industry analysis highlights organoids as a key driver of R&D efficiency.

  2. First IND via Organoid Data

    A drug candidate enters Phase I trials based primarily on organoid-derived safety data.

  3. Large-Scale Biobank Launch

    Major research consortiums establish standardized patient-derived organoid biobanks.

  4. FDA Modernization Act 2.0

    Legislation passed allowing non-animal models for drug testing.

Stories mentioning Organovo 1

pharma Bullish

Pipeline Potential: Mini Lab-Grown Organs Transform Drug Discovery

Mini lab-grown organs, or organoids, are transitioning from research tools to central pillars of the pharmaceutical drug development pipeline. By offering human-relevant models that outperform traditional animal testing, these 3D cultures are set to reduce clinical trial failure rates and accelerate R&D timelines.

2 sources